Show simple item record

dc.contributor.authorCırık, Ahmet Adnan
dc.contributor.authorEvcimik, Muhammed Fatih
dc.contributor.authorÜlfer, Gözde
dc.contributor.authorYiğitbaşı, Türkan
dc.contributor.authorAktaş, Öztürk
dc.date.accessioned2020-09-17T05:19:09Z
dc.date.available2020-09-17T05:19:09Z
dc.date.issued2019en_US
dc.identifier.citationCırık, A. A., Evcimik, M. F., Ülfer, G., Yiğitbaşı, T. ve Aktaş, Ö. (2019). Ischemia-modified albumin levels in patients with idiopathic sudden sensorineural hearing loss. The Turkish Journal of Ear Nose and Throat, 29(1), 21-27. https://dx.doi.org/10.5606/Tr-ENT.2019.43153en_US
dc.identifier.issn2602-4837
dc.identifier.urihttps://dx.doi.org/10.5606/Tr-ENT.2019.43153
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5831
dc.description.abstractObjectives: This study aims to investigate whether serum levels of ischemia-modified albumin (IMA) are associated with idiopathic sudden sensorineural hearing loss (ISSNHL). Patients and Methods: Between December 2015 and June 2017, a total of 17 patients (9 males, 8 females; mean age 49.4±18.0 years; range, 24 to 88 years) with ISSNHL and 24 age- and sex-matched healthy individuals (12 males, 12 females; mean age 44.5±13.3 years; range, 30 to 81 years) as the control group were included in the study. All patients underwent audiometric examination at the time of admission immediately before the beginning of the treatment and weekly after treatment initiation until one month using the Interacoustics AC40 audiometer. Serum IMA levels were evaluated using blood samples from the antecubital vein of both patient and control groups. The samples were centrifuged to separate the serum from the cells. Albumin cobalt binding test was used for IMA measurement. Results: The mean IMA level was 0.374±0.081 absorbance units (ABSU) (range, 0.205 to 0.536) in the study group at the time of diagnosis, 0.358±0.051 ABSU (range, 0.297 to 0.466) in the post-treatment period, at least four weeks after onset, and 0.358±0.053 ABSU (range, 0.281 to 0.434) in the control group. There was no statistically significant difference between the patient and control groups. The IMA levels of the patients with ISSNHL in the post-treatment period were lower than the onset of illness, although this difference was not statically significant (0.440). Conclusion: Our study results demonstrated that serum IMA levels in the patients with ISSNHL did not differ from the control group.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIschemia-Modified Albuminen_US
dc.subjectIdiopathic Sudden Sensorineural Hearing Lossen_US
dc.titleIschemia-modified albumin levels in patients with idiopathic sudden sensorineural hearing lossen_US
dc.typearticleen_US
dc.relation.journalThe Turkish Journal of Ear Nose and Throaten_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kulak Burun Boğaz Hastalıkları Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyokimya Ana Bilim Dalıen_US
dc.authorid0000-0003-0606-864Xen_US
dc.authorid0000-0003-2350-6381en_US
dc.authorid0000-0002-0675-1839en_US
dc.identifier.volume29en_US
dc.identifier.issue1en_US
dc.identifier.startpage21en_US
dc.identifier.endpage27en_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.5606/Tr-ENT.2019.43153en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record